Literature DB >> 22359728

Light chain deposition disease presenting as cholestatic jaundice: a case report.

Prasanna N Kumar.   

Abstract

Light-chain deposition disease (LCDD) is characterized by tissue deposition of the immunoglobulin light chains in multiple organs. These deposits appear similar to amyloid on routine sections, but differ in their staining properties and ultrastructural appearance. The deposits of LCCD are non -Congophilic and do not exhibit a fibrillar ultrastructure; while, the proteinaceous substance seen in primary amyloidosis is Congo red positive and fibrillar. One of the most common organs to be involved in LCDD is the kidney. Earlier reports on cases of LCDD have mostly shown simultaneous liver and renal involvement, there are very few cases in the literature describing LCDD of the liver without renal involvement. This report describes a patient who presented with severe cholestatic jaundice and liver cell failure with normal renal function.

Entities:  

Keywords:  Cholestatic jaundice; Congo Red; Light Chains

Year:  2012        PMID: 22359728      PMCID: PMC3282131          DOI: 10.5001/omj.2012.12

Source DB:  PubMed          Journal:  Oman Med J        ISSN: 1999-768X


  9 in total

1.  Amyloid disease of the bone marrow. Diagnosis by sternal marrow a spiration.

Authors:  R B CONN; R D SUNDBERG
Journal:  Am J Pathol       Date:  1961-01       Impact factor: 4.307

2.  Light chain deposition disease presenting as massive hepatomegaly.

Authors:  Shriram Vaidia Nath; Modisha Peiris; Mark J Bishton; Ellen Maxwell; H Miles Prince
Journal:  Pathology       Date:  2010-04       Impact factor: 5.306

3.  Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.

Authors:  César Samanez; Abel Domingo; M Teresa Cibeira; Rosa Miquel; Manel Soler; Joan Bladé
Journal:  Eur J Haematol       Date:  2006-01       Impact factor: 2.997

4.  Kappa light chain deposition disease of the liver.

Authors:  C M Girelli; G Lodi; F Rocca
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-05       Impact factor: 2.566

5.  Light chain deposition disease presenting with hepatomegaly: an association with amyloid-like fibrils.

Authors:  G Pelletier; M Fabre; P Attali; A Ladouch-Badre; O Ink; E Martin; J P Etienne
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

6.  Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome.

Authors:  Spyros Michopoulos; Kalliopi Petraki; Constantina Petraki; Meletios-Athanasios Dimopoulos
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

7.  Hepatic amyloidosis with light chain deposition disease. A rare association.

Authors:  M A Casiraghi; A De Paoli; A Assi; G Palladini; M T Lavazza; A Beretta; G Gualdoni; R Beretta
Journal:  Dig Liver Dis       Date:  2000-12       Impact factor: 4.088

8.  Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.

Authors:  Katja C Weisel; Michael Böckeler; Leonardo Bianchi; Luigi M Terracciano; Frank Mayer; Lothar Kanz
Journal:  Int J Hematol       Date:  2008-12-20       Impact factor: 2.490

Review 9.  Light chain deposition disease of the liver associated with AL-type amyloidosis and severe cholestasis.

Authors:  G Faa; P Van Eyken; R De Vos; J Fevery; B Van Damme; J De Groote; V J Desmet
Journal:  J Hepatol       Date:  1991-01       Impact factor: 25.083

  9 in total
  2 in total

1.  Primary Amyloidosis Manifesting as Cholestatic Jaundice after Laparoscopic Cholecystectomy.

Authors:  Evangelos P Misiakos; George Bagias; Dina Tiniakos; Konstantinos Roditis; Nick Zavras; Ioannis Papanikolaou; Panagiotis Tsirigotis; Theodore Liakakos; Anastasios Machairas
Journal:  Case Rep Surg       Date:  2015-06-07

2.  Light-Chain Deposition Disease with Prominent Hepatic Involvement.

Authors:  Ana Cristino; Carmen Pais; Renata Silva; Paulo Carrola
Journal:  Eur J Case Rep Intern Med       Date:  2017-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.